FDA Approves Wegovy for Heart Disease Prevention in Landmark Decision

It is a significant development from the US FDA which has just given approval to Novo Nordisk’s Wegovy, a medication initially approved for weight loss, which has now also been approved to reduce the risk of cardiovascular events in adults. This groundbreaking decision marks Wegovy as the first weight-loss medication to be approved for preventing life-threatening heart conditions in individuals with cardiovascular disease who are overweight or obese.